Positive Results From Phase 2 Clinical Study Of NKTR-102 In Metastatic Breast Cancer

[News]

Nektar Therapeutics (Nasdaq: NKTR) announced that positive results from the company's Phase 2 clinical study of NKTR-102 in patients with metastatic breast cancer were presented at the ASCO 2011 Breast Cancer Symposium in San Francisco, California...

More... (http://www.medicalnewstoday.com/releases/234208.php)

[kykeon22]

Inspiring, excinting, amazing.

Research is building a truly arsenal against breast cancer.